Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Prof Marais awarded the first UFS Book Prize for Distinguished Scholarship
2015-03-19

Prof Kobus Marais

Prof Kobus Marais, from the Department of Linguistics and Language Practice, was recently awarded the UFS Book Prize for Distinguished Scholarship for 2014.

The prize, awarded for its first time in 2014, consists of an inscribed certificate of honour with a monetary award of R50 000 paid into Marais’s research entity. The book for which Marais received this award is Translation Theory and Development Studies: A Complex Theory Approach (2014, Routledge, New York).

“It falls within the discipline of translation studies, but it is actually an interdisciplinary approach, linking translation studies and development studies,” says Marais.

Therefore, it aims to provide a philosophical underpinning to translation, and relate translation to development.

“The second aim flows from the first section’s argument that societies emerge out of, amongst others, complex translational interactions amongst individuals,” Marais says. “It will do so by conceptualising translation from a complexity and emergence point of view, and by relating this view on emergent semiotics to some of the most recent social research.”

It fulfils its aim further by providing empirical data from the South African context concerning the relationship between translation and development. The book intends to be interdisciplinary in nature, and to foster interdisciplinary research and dialogue by relating the newest trends in translation theory, i.e. agency theory in the sociology of translation, to development theory within sociology. 

“Data are drawn from fields that have received very little if any attention in translation studies, i.e. local economic development, the knowledge economy, and the informal economy, says Marais.”

The UFS Book Prize for Distinguished Scholarship was initiated in 2014 to bestow recognition on any permanent staff member of the UFS for outstanding publications which consist of research published as an original book, on the condition that the greater part (50% or more) of the book has not been published previously. This stimulates the production of significant and original contributions of international quality by our staff. In this way, the UFS is striving, through a series of award-winning books, to enhance the quality of specialised works published by our staff members.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept